Written and maintained by CASRAI Editorial Board
Published · Last updated
On this page
The Framingham Risk Score (FRS) is a multivariable, sex-specific clinical prediction algorithm developed from longitudinal cohort data in the Framingham Heart Study to estimate the 10-year probability of incident cardiovascular events in adults without pre-existing cardiovascular disease. First formalized for coronary heart disease (CHD) by Wilson et al. in Circulation (1998) and expanded to a composite general cardiovascular disease (CVD) endpoint by D’Agostino et al. in Circulation (2008), the Framingham Risk Score serves as a benchmark model in cardiovascular epidemiology, preventive cardiology trials, and biostatistical calibration studies alongside newer calculators such as the ASCVD Risk Estimator and acute care tools like the HEART Score.
What Is the Framingham Risk Score and How Is It Used in Clinical Research and Healthcare?
In both primary care prevention and clinical trial eligibility screening, the Framingham Risk Score translates continuous and categorical patient risk factors into an absolute 10-year event probability. Two landmark formulations are widely cited in peer-reviewed research and clinical guidelines:
- 1998 Hard CHD / Total CHD Model (Wilson et al., Circulation 1998;97:1837–1847): Derived from 2,489 men and 2,856 women aged 30 to 74 years from the Framingham Original and Offspring cohorts followed for 12 years. The NCEP Adult Treatment Panel III (ATP III) adapted this model to predict 10-year “hard CHD” (myocardial infarction and coronary death).
- 2008 General CVD Risk Profile (D’Agostino et al., Circulation 2008;117:743–753, PMC2719252): Derived from 8,491 Framingham participants (3,969 men and 4,522 women) aged 30 to 74 years free of CVD at baseline, during which 1,174 participants developed a first CVD event over 12 years of follow-up. The composite outcome encompasses coronary death, myocardial infarction, coronary insufficiency, angina, ischemic stroke, hemorrhagic stroke, transient ischemic attack, peripheral artery disease, and heart failure.
Mathematical Formulation and Predictor Variables
Rather than relying solely on integer point tables, clinical informatics systems and research pipelines compute the continuous Framingham Risk Score using a sex-specific Cox proportional hazards regression equation:
P(10-year CVD) = 1 - S_0(10) ^ exp( Sum[ beta_i * X_i ] - Sum[ beta_i * X_mean_i ] )
In the 2008 D’Agostino laboratory-based model, the continuous predictors are natural-log transformed (ln(Age), ln(Total Cholesterol), ln(HDL-C), and ln(Systolic Blood Pressure) stratified by whether hypertension is treated or untreated) and combined with binary indicators for current cigarette smoking and diabetes mellitus. In the 2008 model, the 10-year baseline survival probability S_0(10) is 0.88936 for men and 0.95012 for women, yielding C-statistics (discrimination) of 0.763 in men and 0.793 in women. A parallel non-laboratory office-based version substitutes ln(Body Mass Index) for total and HDL cholesterol when lipid panels are unavailable.
What Standards or Regulatory Requirements Govern the Framingham Risk Score?
Clinical guidelines and methodological validation standards define how the Framingham Risk Score is categorized, calibrated, and reported in clinical research:
| Guideline / Standard | Risk Categorization & Methodological Rule | Research & Clinical Application |
|---|---|---|
| NHLBI NCEP ATP III (2001/2002) | 10-year hard CHD risk <10% (Low Risk), 10%–20% (Intermediate Risk), >20% (High Risk / CHD Risk Equivalent) | Stratifying asymptomatic participants in lipid-lowering trials and preventive cardiology cohorts |
| 2008 General CVD Thresholds (D’Agostino et al.) | Broad composite CVD endpoint typically categorized as <10% (Low), 10%–20% (Intermediate), and >20% (High) | Evaluating total global vascular burden across coronary, cerebrovascular, and peripheral arterial beds |
| Recalibration & TRIPOD Validation Standards | Assessment of calibration-in-the-large, calibration slope, and Harrell’s C-index when transporting equations to non-Framingham cohorts | Adjusting baseline survival S_0(10) and mean risk factor levels (D’Agostino et al., JAMA 2001) to prevent systematic overestimation in multi-ethnic or lower-incidence populations |
How Does the Framingham Risk Score Integrate with EHR and Health Informatics Workflows?
In hospital and ambulatory electronic health records (EHRs) as well as point-of-care reference platforms such as MDCalc, the Framingham Risk Score is automated by querying structured clinical data elements via HL7 Fast Healthcare Interoperability Resources (FHIR):
- Patient & Observation Resources: Patient birthDate and administrative gender from the FHIR
Patientresource; systolic blood pressure (LOINC8480-6), serum total cholesterol (LOINC2093-3), serum HDL cholesterol (LOINC2085-9), and smoking status (LOINC72166-2) from FHIRObservationresources. - Medication & Condition Lookup: Active antihypertensive therapy is verified from FHIR
MedicationRequestorMedicationStatementresources mapped to RxNorm antihypertensive classes, while diabetes status is extracted from FHIRConditionICD-10-CM/SNOMED CT problem lists or HbA1c observations (LOINC4548-4). - Clinical Decision Support (CDS) Hooks: Using the Cox regression coefficients directly in a SMART on FHIR widget or CDS Hook service avoids rounding artifacts introduced by integer lookup tables and flags missing lipid results exceeding protocol staleness windows.
Frequently Asked Questions
What is the Framingham Risk Score and how is it used in clinical research and healthcare?
The Framingham Risk Score (FRS) is a sex-specific multivariable statistical algorithm derived from the Framingham Heart Study that estimates an asymptomatic adult’s 10-year probability of developing coronary heart disease (Wilson et al., 1998) or general cardiovascular disease (D’Agostino et al., 2008).
What standards or regulatory requirements govern the Framingham Risk Score?
The Framingham Risk Score was operationalized in the NHLBI Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III, 2001/2002) and continues to be evaluated in clinical studies alongside the 2013 ACC/AHA Pooled Cohort Equations and TRIPOD reporting standards.
How does the Framingham Risk Score integrate with EHR and health informatics workflows?
Health informatics systems integrate the Framingham Risk Score using LOINC observation codes for age, systolic blood pressure, total and HDL cholesterol, smoking status, and antihypertensive medication records via HL7 FHIR Clinical Decision Support (CDS) Hooks and SMART on FHIR applications.
Sources
- D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. “General cardiovascular risk profile for use in primary care: the Framingham Heart Study.” Circulation. 2008;117(6):743–753. https://pmc.ncbi.nlm.nih.gov/articles/PMC2719252/
- Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. “Prediction of coronary heart disease using risk factor categories.” Circulation. 1998;97(18):1837–1847. https://pubmed.ncbi.nlm.nih.gov/9603539/
- Framingham Heart Study. Cardiovascular Disease (10-Year Risk) Functions and Coefficients. https://www.framinghamheartstudy.org/fhs-risk-functions/cardiovascular-disease-10-year-risk/







